Page 255 - Vitamin D and Cancer

242 C.M. Barnett and T.M. Beer

19. Hsu JY, Feldman D, McNeal JE et al (2001) Reduced 1alpha-hydroxylase activity in human
prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin
D3-induced growth inhibition. Cancer Res 61:2852–2856
20. Chen TC (2008) 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of
tumor suppressor in the prostate. Anticancer Res 28:2015–2017
21. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality:
a review (United States). Cancer Causes Control 16:83–95
22. Hidalgo AA, Paredes R, Garcia VM et al (2007) Altered VDR-mediated transcriptional
activity in prostate cancer stroma. J Steroid Biochem Mol Biol 103:731–736
23. Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the
second decade. Cell 83:835–839
24. Nanes MS, Kuno H, Demay MB et al (1994) A single up-stream element confers responsive-
ness to 1, 25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene.
Endocrinology 134:1113–1120
25. Koszewski NJ, Reinhardt TA, Horst RL (1996) Vitamin D receptor interactions with the
murine osteopontin response element. J Steroid Biochem Mol Biol 59:377–388
26. Liu M, Lee MH, Cohen M et al (1996) Transcriptional activation of the Cdk inhibitor p21
by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.
Genes Dev 10:142–153
27. Jiang F, Li P, Fornace AJ Jr et al (2003) G2/M arrest by 1, 25-dihydroxyvitamin D3 in ovarian
cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem
278:48030–48040
28. Murayama A, Kim MS, Yanagisawa J et al (2004) Transrepression by a liganded nuclear
receptor via a bHLH activator through co-regulator switching. EMBO J 23:1598–1608
29. Hawa NS, O’Riordan JL, Farrow SM (1996) Functional analysis of vitamin D response elements
in the parathyroid hormone gene and a comparison with the osteocalcin gene. Biochem Biophys
Res Commun 228:352–357
30. Maestro B, Davila N, Carranza MC et al (2003) Identification of a Vitamin D response element
in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 84:223–230
31. Guzey M, Kitada S, Reed JC (2002) Apoptosis induction by 1alpha, 25-dihydroxyvitamin
D3 in prostate cancer. Mol Cancer Ther 1:667–677
32. Nemere I, Yoshimoto Y, Norman AW (1984) Calcium transport in perfused duodena from
normal chicks: enhancement within fourteen minutes of exposure to 1, 25-dihydroxyvitamin
D3. Endocrinology 115:1476–1483
33. Beno DW, Brady LM, Bissonnette M et al (1995) Protein kinase C and mitogen-activated
protein kinase are required for 1, 25-dihydroxyvitamin D3-stimulated Egr induction. J Biol
Chem 270:3642–3647
34. Morelli S, Buitrago C, Boland R et al (2001) The stimulation of MAP kinase by 1, 25(OH)
(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium. Mol
Cell Endocrinol 173:41–52
35. Rossi AM, Capiati DA, Picotto G et al (2004) MAPK inhibition by 1alpha, 25(OH)2-
Vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src.
J Steroid Biochem Mol Biol 89–90:287–290
36. Wali RK, Baum CL, Sitrin MD et al (1990) 1, 25(OH)2 vitamin D3 stimulates membrane
phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat
colonic epithelium. J Clin Invest 85:1296–1303
37. Larsson D, Hagberg M, Malek N et al (2008) Membrane initiated signaling by 1, 25alpha-
dihydroxyvitamin D3 in LNCaP prostate cancer cells. Adv Exp Med Biol 617:573–579
38. Berndt SI, Dodson JL, Huang WY et al (2006) A systematic review of vitamin D receptor
gene polymorphisms and prostate cancer risk. J Urol 175:1613–1623
39. Cicek MS, Liu X, Schumacher FR et al (2006) Vitamin D receptor genotypes/haplotypes and
prostate cancer risk. Cancer Epidemiol Biomarkers Prev 15:2549–2552
40. Ma J, Stampfer MJ, Gann PH et al (1998) Vitamin D receptor polymorphisms, circulating
vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer
Epidemiol Biomarkers Prev 7:385–390